Your browser doesn't support javascript.
loading
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022.
Armstrong, Deborah K; Alvarez, Ronald D; Backes, Floor J; Bakkum-Gamez, Jamie N; Barroilhet, Lisa; Behbakht, Kian; Berchuck, Andrew; Chen, Lee-May; Chitiyo, Viola C; Cristea, Mihaela; DeRosa, Maria; Eisenhauer, Eric L; Gershenson, David M; Gray, Heidi J; Grisham, Rachel; Hakam, Ardeshir; Jain, Angela; Karam, Amer; Konecny, Gottfried E; Leath, Charles A; Leiserowitz, Gary; Liu, Joyce; Martin, Lainie; Matei, Daniela; McHale, Michael; McLean, Karen; Miller, David S; Percac-Lima, Sanja; Remmenga, Steven W; Schorge, John; Stewart, Daphne; Thaker, Premal H; Vargas, Roberto; Hendrickson, Andrea Wahner; Werner, Theresa L; Zsiros, Emese; Dwyer, Mary A; Hang, Lisa.
  • Armstrong DK; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
  • Alvarez RD; Vanderbilt-Ingram Cancer Center.
  • Backes FJ; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute.
  • Bakkum-Gamez JN; Mayo Clinic Cancer Center.
  • Barroilhet L; University of Wisconsin Carbone Cancer Center.
  • Behbakht K; University of Colorado Cancer Center.
  • Berchuck A; Duke Cancer Institute.
  • Chen LM; UCSF Helen Diller Family Comprehensive Cancer Center.
  • Chitiyo VC; Memorial Sloan Kettering Cancer Center.
  • Cristea M; City of Hope National Medical Center.
  • DeRosa M; Patient advocate.
  • Eisenhauer EL; Massachusetts General Hospital Cancer Center.
  • Gershenson DM; The University of Texas MD Anderson Cancer Center.
  • Gray HJ; University of Washington/Seattle Cancer Care Alliance.
  • Grisham R; Memorial Sloan Kettering Cancer Center.
  • Hakam A; Moffitt Cancer Center.
  • Jain A; Fox Chase Cancer Center.
  • Karam A; Stanford Cancer Institute.
  • Konecny GE; UCLA Jonsson Comprehensive Cancer Center.
  • Leath CA; O'Neal Comprehensive Cancer Center at UAB.
  • Leiserowitz G; UC Davis Comprehensive Cancer Center.
  • Liu J; Dana-Farber/Brigham and Women's Cancer Center.
  • Martin L; Abramson Cancer Center at the University of Pennsylvania.
  • Matei D; Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
  • McHale M; UC San Diego Moores Cancer Center.
  • McLean K; University of Michigan Rogel Cancer Center.
  • Miller DS; UT Southwestern Simmons Comprehensive Cancer Center.
  • Percac-Lima S; Massachusetts General Hospital Cancer Center.
  • Remmenga SW; Fred & Pamela Buffett Cancer Center.
  • Schorge J; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center.
  • Stewart D; City of Hope National Medical Center.
  • Thaker PH; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine.
  • Vargas R; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute.
  • Hendrickson AW; Mayo Clinic Cancer Center.
  • Werner TL; Huntsman Cancer Institute at the University of Utah.
  • Zsiros E; Roswell Park Comprehensive Cancer Center; and.
  • Dwyer MA; National Comprehensive Cancer Network.
  • Hang L; National Comprehensive Cancer Network.
J Natl Compr Canc Netw ; 20(9): 972-980, 2022 09.
Article en En | MEDLINE | ID: mdl-36075393
ABSTRACT
Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States, with less than half of patients living >5 years following diagnosis. The NCCN Guidelines for Ovarian Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up for patients with ovarian, fallopian tube, and primary peritoneal cancers. These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines, including revised guidance on alternative chemotherapy regimens for patients with advanced age and/or comorbidities, a new algorithm for recurrent low-grade serous carcinoma based on developing research and novel therapeutic agents, and updated language regarding tumor molecular analysis applications in ovarian cancer.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Neoplasias Peritoneales / Cistadenocarcinoma Seroso Tipo de estudio: Diagnostic_studies / Guideline / Qualitative_research Límite: Female / Humans País como asunto: America do norte Idioma: En Año: 2022 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Neoplasias Peritoneales / Cistadenocarcinoma Seroso Tipo de estudio: Diagnostic_studies / Guideline / Qualitative_research Límite: Female / Humans País como asunto: America do norte Idioma: En Año: 2022 Tipo del documento: Article